期刊文献+

吉西他滨联合多西他赛治疗晚期软组织肉瘤11例 被引量:3

Gemcitabine/Docetaxel Combination as Second-line Treatment for 11 Advanced Soft Tissue Sarcoma Patients
下载PDF
导出
摘要 目的:探讨吉西他滨联合多西他赛治疗晚期软组织肉瘤的临床疗效。方法:收集11例对一线化疗药物耐药的晚期软组织肉瘤患者,应用吉西他滨(剂量为900mg/m^2,第1和第8天)联合多西他赛(剂量为100 mg/m^2,第8天)每3周重复给药。如患者曾经接受放疗,吉西他滨剂量减为675 mg/m^2,多西他赛剂量减为75mg/m^2。结果:接受化疗的患者总有效率(CR+PR+SD)为54.5%。中位随访时间为19(1~36)个月,中位总生存期为15.4个月(95%CI:8.012~21.598)和中位无进展生存期为8.4个月(95%CI:7.342~8.768)。12个月和36个月的生存率分别是81.8%和27.3%。吉西他滨联合多西他赛治疗软组织肉瘤最常见的非血液学不良反应是黏膜炎,对症处理明显好转。结论:吉西他滨联合多西他赛作为二线化疗药物治疗晚期软组织肉瘤患者具有较好的临床疗效,且有较好的耐受性,本研究结论为该方案的大样本临床试验提供了依据。 Objective: To investigate the promising anti-tumor effects of gemcitabine and/or docetaxel on metastatic or unresect- able soft tissue sarcomas. Methods: Data of 11 patients with advanced soft tissue sarcomas refractory to first-line chemotherapy treat- ment were enrolled in this study. They received gemcitabine alone or gemcitabine/docetaxel combination as follows: 900 mg/m^2 gem- citabine on days 1 and 8, and 100 mg/m^2 docetaxel on day 8. The regimen was repeated every 3 weeks. When irradiation was conducted before drug therapy, the doses were reduced to 675 mg/m^2 gemcitabine on days 1 and 8, and 75 mg/m^2 docetaxel on day 8. The regimen was repeated every 3 weeks, Results: The gemcitabine/docetaxel combination was well tolerated. The most commonly observed hema- tologic toxicity of the combined therapy was neutropenia ( 45.5 % ). The most common non-hematologic toxicity observed was mucosi- tis ( 45.5 % ). The overall response was 45.5%. Follow-ups ranging from 1 month to 36 months ( median = 19 months ) revealed that the median overall survival time was 15.4 months ( 95% CI = 8.012 - 21.598 ) and the median progression-free survival time was 8.4 months ( 95 % CI = 7.342 - 8.768 ). The one- and two-year survival rates were 81.8 % and 27.3 %, respectively. Conclusion: A gem- citabine/docetaxel regimen as second-line treatment for patients with advanced soft tissues sarcomas is effective and has acceptable toxicities. These results should be evaluated in a large-sample Ⅲ trial.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2012年第12期853-856,共4页 Chinese Journal of Clinical Oncology
关键词 晚期软组织肉瘤 二线化疗 吉西他滨 多西他赛 Advanced soft tissue sarcomas Second-line chemotherapy Gemcitabine Docetaxel
  • 相关文献

参考文献13

  • 1Singer S, Demetri GD, Baldini EH, et al. Management of soft-tis- sue sarcomas: an overview and update[J].Lancet Oncol, 2000, 1: 75-85.
  • 2Clark MA, Fisher C, Judson I, et aI. Soft-tissue sarcomas in adults [J]. N EnglJ Med, 2005, 353(7): 701-711.
  • 3Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predic- tive factors for outcome to first-line ifosfamide-contalning chemo- therapy for adult patients with advanced soft tissue sarcomas: an ex- ploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTG-STBSG) [J]. Eur j Cancer, 2010, 46(1): 72-83.
  • 4Fowler JD, Brown JA, Johnson KA, et al. Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization cata- lyzed by human mitochondrial DNA polymerase[J]. J Biol Chem, 2008, 283 (22) : 15339-15348.
  • 5Look KY, Sandler A, BlessingJA, et al. Phase II trial of gemcitabine as second-line chemotherapy for uterine leiomyosarcoma: a Gyne- cologic Oncology Group (GOG) Study[J]. Gynecol Oncol, 2004, 92 (9) : 644-647.
  • 6Lee HY, Shin SJ, Kim HS, et al. Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis[J]. Cancer Res Treat, 2012, 44(1): 43-49.
  • 7Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable Ieiomyosarcoma: results of a phase II trial[J].J Clin Oncol, 2002, 20(12): 2824-2831.
  • 8Trotti A, Colevas AD, Setser A, et al. GTGAE v3.0: development of a comprehensive grading system for the adverse effects of cancertreatmentS. Semin Radiat Oncol, 2003, 13(3): 176-181.
  • 9Italiano A, Toulmonde M, Lortal B,et al. "Metronomic" chemother- apy in advanced soft tissue sarcomas[J]. Cancer Chemother Phar- macol, 2010, 66(1):197-202.
  • 10MaurelJ, Ldpez-Pousa A, de Las Peas R, et al. Efficacy of sequen- tial high-dose doxorubicin and ifosfamide compared with stan- dard-dose doxorubicin in patients with advanced soft tissue sarco- ma: an open-label randomized phase II study of the Spanish group for research on sarcomas[J].J Clin Oncol, 2009, 27(11): 1893-1898.

同被引文献29

  • 1蔡铭泉,李晓虹,张映红,吕晓君.单药沙利度胺治疗晚期软组织肉瘤的临床疗效观察[J].中国全科医学,2013,16(8):930-932. 被引量:2
  • 2Liu ZL, Wang G, Peng AF, et al. Fatty acid synthase expressionin osteosarcoma and its correlation with pulmonary metastasis[ J].Oncol Lett, 2012,4(5) :878-882.
  • 3Lamb S,Reavill D,Wojcieszyn J,et al. Osteosarcoma of the tib-iotarsus with possible pulmonary metastasis in a ring-necked dove(Streptopelia risoria) [ J] . J Avian Med Surg,2014,28 ( 1 ) : 50-56.
  • 4Mebarki M,Medjahedi A, Menemani A, et al. Osteosarcomapulmonary metastasis mimicking abnormal skeletal uptake in bonescan: utility of SPECT/CT[ J]. Clin Nucl Med, 2013,38(10):e392-e394.
  • 5Taylor PT, Haverstick D. Re; New guidelines to evaluate the re-sponse to treatment in solid tumors ( ovarian cancer) [ J]. J NatlCancer Inst, 2005,97(2) :152.
  • 6Thompson RJ, Cheng EY,Clohisy DR, et al. Results oftreatment for metastatic osteosarcoma with neoadjuvant chemother-apy and surgery [ J ] . Clin Orthop Relat Res,2002 ’ 397 : 240-247.
  • 7Letoumeau PA, Xiao L, Halting MT, et al. Location ofpulmonary metastasis in pediatric osteosarcoma is predictive ofoutcome[ J] . J Pediatr Surg, 2011,46(7) : 1333-1337.
  • 8Chen F, Miyahara R, Bando T, et al. Repeat resection of pulmo-nary metastasis is beneficial for patients with osteosarcoma of theextremities[ J] . Interact Cardiovasc Thorac Surg, 2009,9(4):649-653.
  • 9Duffaud F, Egerer G,Ferrari S, et al. A phase K trial ofsecond-line pemetrexed in adults with advanced/metastatic osteo-sarcoma[J]. Eur J Cancer, 2012,48(4) :564-570.
  • 100,Day K, Gorlick R. Novel therapeutic agents for osteosarcoma[J]. Expert Rev Anticancer Ther, 2009,9(4) :511-523.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部